Camrelizumab Injection 200?mg – Low price wholesale comparison

DescriptionCamrelizumab (SHR?1210) is a humanized, high-affinity IgG4 ? monoclonal antibody targeting programmed cell death protein?1 (PD?1). By disrupting PD?1/PD?L1 interactions, it reinvigorates T and B lymphocytes and NK cells, enabling immunologic cancer cell recognition?. Widely studied in over 5,000 patients across multiple Phase?II/III trials, camrelizumab has shown promising antitumor activity, notably in hepatocellular carcinoma and Hodgkin lymphoma?.Developed by Alexion Pharma International at the Athlone facility in Ireland, this vial is authorized for research use. China NMPA registration is SJ20250016, drug code 86982467000031. ? For lab research only—not for therapeutic or diagnostic use. Contents hide 1 Camrelizumab Injection Product Specifications 2 Camrelizumab Injection Mechanism & Research Applications 3 Camrelizumab Injection Side Effects (Research Observations) 4 Safety & Handling 5 Core Keywords 6 Research Use Disclaimer Camrelizumab Injection Product SpecificationsParameterDetailsProduct NameCamrelizumab Injection (Zhengguo)Generic NameCamrelizumab (SHR?1210)CAS Number1798286?48?2Molecular TypeHumanized IgG4 ? monoclonal antibodyMechanism of ActionPD?1 immune checkpoint inhibitionDosage FormSterile injectable solution (vial)Strength200?mg in 11?mL vialPackaging1 vial per boxApproval NumberSJ20250016 (China NMPA)Product Code86982467000031ManufacturerAlexion Pharma International Operations (Ireland)BarcodePending – contact for registrationStorage ConditionsStore at 2–8?°C; protect from lightIntended UseLaboratory research onlyCamrelizumab Injection Mechanism & Research ApplicationsCamrelizumab binds PD?1 receptors on T, B, and NK cells, blocking their inhibition by PD?L1, and restoring anti?tumor immunity?. It has been used extensively in:Immuno-oncology studies (hepatocellular carcinoma, melanoma, Hodgkin lymphoma)Combination studies with VEGFR inhibitors and chemotherapy?Investigations into immune-related adverse events like cutaneous capillary proliferation?Biomarker research (PD?L1 expression, T-cell activation assays)Camrelizumab Injection Side Effects (Research Observations)Based on clinical trial data, common immune-related events include:Reactive cutaneous capillary endothelial proliferation (RCCEP) – typically mild and reversible?Infusion-associated effects: fever, fatigue, rash, pruritusRare immune-related organ toxicities: hepatitis, colitis, pneumonitisInclude immune toxicity monitoring when used in animal models.Safety & HandlingUse Restriction: For laboratory research only – not for human or veterinary useHandling: Use aseptic technique and lab-grade PPE (gloves, gown, eye protection)Storage: Between 2–8?°C; protect from lightDisposal: Dispose as per institutional biohazard and pharmaceutical regulationsCore KeywordsCamrelizumab injection, Zhengguo camrelizumab, anti?PD?1 monoclonal antibody, immuno-oncology research, lab-grade PD?1 inhibitor, 1100?mg camrelizumab vial, NMPA SJ20250016 camrelizumab, Alexion camrelizumab, wholesale camrelizumab injectionResearch Use DisclaimerThis product is intended exclusively for laboratory research use and is not approved for diagnostic, therapeutic, clinical, or veterinary applications. Misuse may pose safety or regulatory concerns. Always follow institutional biosafety and handling guidelines.